Sumitomo Dainippon Pharma Co., Ltd.
GPTKB entity
Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Hiroshi_Nomura
|
| gptkbp:country |
gptkb:Japan
|
| gptkbp:formerName |
gptkb:Dainippon_Sumitomo_Pharma_Co.,_Ltd.
|
| gptkbp:founded |
2005
|
| gptkbp:headquartersLocation |
gptkb:Osaka,_Japan
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:nativeName |
gptkb:住友ファーマ株式会社
|
| gptkbp:numberOfEmployees |
about 7,000
|
| gptkbp:officialWebsite |
https://www.ds-pharma.com/
|
| gptkbp:parentCompany |
gptkb:Sumitomo_Chemical
|
| gptkbp:predecessor |
gptkb:Dainippon_Pharmaceutical
gptkb:Sumitomo_Pharmaceuticals |
| gptkbp:product |
gptkb:Latuda
gptkb:Lunesta gptkb:Cymbalta |
| gptkbp:researchInterest |
gptkb:diabetes
neurology oncology psychiatry |
| gptkbp:servesArea |
worldwide
|
| gptkbp:stockExchange |
gptkb:Tokyo_Stock_Exchange
|
| gptkbp:stockSymbol |
4506
|
| gptkbp:subsidiary |
gptkb:Sumitomo_Pharma_America
|
| gptkbp:bfsParent |
gptkb:Sumitomo_Dainippon_Pharma
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sumitomo Dainippon Pharma Co., Ltd.
|